Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

Next Previous
Trial Profile

A Phase I Study of Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Birinapant (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 13 Feb 2020 According to a Medivir AB media release, this study is sponsored and funded as part of the National Cancer Institute's Cancer Treatment Evaluation Program.
  • 02 Apr 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Apr 2019 to 9 Apr 2019.
  • 26 Mar 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 29 Mar 2019 to 1 Apr 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top